GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update
by Doug Wharley · The Cerbat GemGT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totaling 2,075,177 shares, a growth of 243.3% from the April 30th total of 604,557 shares. Based on an average daily trading volume, of 2,320,983 shares, the short-interest ratio is currently 0.9 days. Currently, 6.0% of the shares of the stock are short sold.
Hedge Funds Weigh In On GT Biopharma
An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC purchased a new position in shares of GT Biopharma, Inc. (NASDAQ:GTBP – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned 0.47% of GT Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). 8.15% of the stock is currently owned by institutional investors and hedge funds.
GT Biopharma Stock Performance
Shares of NASDAQ:GTBP traded up $0.04 during mid-day trading on Friday, reaching $0.48. 2,059,462 shares of the company’s stock were exchanged, compared to its average volume of 1,254,953. The firm has a market capitalization of $17.42 million, a price-to-earnings ratio of -0.08 and a beta of 0.64. The business’s fifty day moving average price is $0.39 and its 200-day moving average price is $0.55. GT Biopharma has a twelve month low of $0.26 and a twelve month high of $3.85.
GT Biopharma (NASDAQ:GTBP – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Analysts predict that GT Biopharma will post -0.34 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a research report on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on GTBP
GT Biopharma Company Profile
GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.
The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).